Nih grants $1.44m to cancer targeted technology to support the ongoing prostate cancer clinical trial of a promising new radiotherapeutic, ctt1403

Cancer targeted technology receives $1.44m in year 2 of sbir phase iib grant to fund clinical trial of new psma-targeted therapeutic agent, ctt1403.

AYTU Ratings Summary

AYTU Quant Ranking